Equillium spikes 22% after early Phase 2 data for lupus nephritis candidate [Seeking Alpha]
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Equillium spikes 22% after early Phase 2 data for lupus nephritis candidateSep. 27, 2022 10:20 AM ETEquillium, Inc. (EQ)By:Dulan LokuwithanaSA News EditorBeritKNASDAQ:added ~22% ilead asset itolizumab in lupus nephritis (LN).The ongoing second portion of the Phase 1b trial is designed to test the subcutaneous delivery of 1.6 mg/kg itolizumab every two weeks over 24 weeks in up to 20 patients.Highlights of the results indicate 3 of 6 (50%) subjects achieved Complete Response (CR) by week 28, while 2 of 6 (33%) subjects reached partial response (PR), including 4 of 6 (67%) of those who indicated more than 80% decline in urine protein creatinine ratio (UPCR).In those subjects who received more than one dose, the average UPCR decline stood at 60%, while 8 of 12 (67%) showed an over 50% reduction in UPCR. The data were based on patients with high proteinuria.The drug was found to be safe and well tolerated in general, with no drug-related serious adverse events. Further data from thestudy
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Equillium, Inc. (NASDAQ: EQ) had its price target raised by analysts at HC Wainwright from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- 5 Stocks That More Than Doubled in Q1 With More Gains Ahead [Yahoo! Finance]Yahoo! Finance
- Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis [Yahoo! Finance]Yahoo! Finance
EQ
Earnings
- 3/25/24 - Beat
EQ
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- EQ's page on the SEC website